2023 Fourth Quarter Earnings (unaudited) Mike Roman Chairman of the Board and Chief Executive Officer Monish Patolawala President and Chief Financial Officer Bruce Jermeland Senior Vice President, Investor Relations -- 1 of 24 -- 2 2023 Q4 Earnings | January 23, 2024. All rights reserved. This presentation contains forward-looking information about 3M’s financial results and estimates and business prospects that involve substantial risks and uncertainties. You can identify these statements by the use of words such as “plan,” “expect,” “aim,” “believe,” “project,” “target,” “anticipate,” “intend,” “estimate,” “will,” “should,” “could,” “would,” “forecast” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) worldwide economic, political, regulatory, international trade, geopolitical, capital markets and other external conditions and other factors beyond the Company’s control, including inflation, recession, military conflicts, natural and other disasters or climate change affecting the operations of the Company or its customers and suppliers; (2) foreign currency exchange rates and fluctuations in those rates; (3) risks related to certain fluorochemicals, including liabilities related to claims, lawsuits, and government regulatory proceedings concerning various PFAS-related products and chemistries, as well as risks related to the Company’s plans to exit PFAS manufacturing and discontinue use of PFAS across its product portfolio; (4) risks related to the proposed class-action settlement (“PWS Settlement”) to resolve claims by public water systems in the United States regarding PFAS, including whether court approval of the PWS Settlement will be obtained, whether the number of plaintiffs that opt out of the PWS Settlement will exceed current expectations or will exceed the level that would permit 3M to terminate the PWS Settlement (and whether 3M will elect to terminate the PWS Settlement if this occurs), whether the PWS Settlement is appealed, the timing and amount of payments made under the PWS Settlement, and the impact of the PWS Settlement on other PFAS-related matters; (5) legal proceedings, including significant developments that could occur in the legal and regulatory proceedings described in the Company’s Annual Report on Form 10-K for the year ended Dec. 31, 2022 and any subsequent quarterly reports on Form 10-Q (the “Reports”); (6) competitive conditions and customer preferences; (7) the timing and market acceptance of new product and service offerings; (8) the availability and cost of purchased components, compounds, raw materials and energy due to shortages, increased demand and wages, supply chain interruptions, or natural or other disasters; (9) unanticipated problems or delays with the phased implementation of a global enterprise resource planning (ERP) system, or security breaches and other disruptions to the Company’s information technology infrastructure; (10) the impact of acquisitions, strategic alliances, divestitures, and other strategic events resulting from portfolio management actions and other evolving business strategies; (11) operational execution, including the extent to which the Company can realize the benefits of planned productivity improvements, as well as the impact of organizational restructuring activities; (12) financial market risks that may affect the Company’s funding obligations under defined benefit pension and postretirement plans; (13) the Company’s credit ratings and its cost of capital; (14) tax-related external conditions, including changes in tax rates, laws or regulations; (15) matters relating to the proposed spin-off of the Company's Health Care business, including whether the transaction will be completed, or if completed, will be on the expected terms; the risk that the expected benefits will not be realized; the risk that the costs or dis-synergies will exceed the anticipated amounts; the ability to satisfy the various closing conditions; potential business disruption; the diversion of management time; the impact of the transaction (or its pendency) on the Company's ability to retain talent; potential impacts on the Company's relationships with its customers, suppliers, employees, regulators and other counterparties; the ability to realize the desired tax treatment (including whether an Internal Revenue Service private letter ruling will be sought or obtained); the risk that any consents or approvals required will not be obtained; risks associated with financings that may be undertaken and indebtedness that may be incurred in connection with the transaction; (16) matters relating to the proposed spin-off of the Company’s Health Care business; and (17) matters relating to Combat Arms Earplugs (“CAE”), including those relating to the August 2023 settlement that is intended to resolve, to the fullest extent possible, all litigation and alleged claims involving the CAE sold or manufactured by the Company’s subsidiary Aearo Technologies and certain of its affiliates (“Aearo Entities”) and/or 3M (“CAE Settlement”), including, but not limited to, whether the anticipated participation by plaintiffs in the CAE Settlement will be achieved, whether the number of plaintiffs that participate in the CAE Settlement will meet current expectations or will fall below the level that would permit 3M to terminate the CAE Settlement (and whether 3M will elect to terminate the CAE Settlement if this occurs), whether there will be a significant number of future claims by plaintiffs that decline to participate in the CAE Settlement, whether the CAE Settlement is appealed or challenged, matters related to the potential issuance of the equity securities that are contemplated to be part of the CAE Settlement, the filing of additional, or the outcome of any other pending or future, litigation relating to the products that are the subject of the CAE Settlement, or changes in related laws or regulations. Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located in the Reports under “Cautionary Note Concerning Factors That May Affect Future Results” and “Risk Factors” in Part I, Items 1 and 1A (Annual Report) and in Part I, Item 2 and Part II, Item 1A (Quarterly Reports). The Company assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments. Note on non-GAAP financial measures This presentation refers to certain non-GAAP financial measures. Refer to 3M’s January 23, 2024, press release for descriptions of non-GAAP financial measures such as adjusted net sales (and adjusted sales change); adjusted purchases of property, plant and equipment (also referred to as adjusted capital expenditures); adjusted net cash provided by (used in) operating activities; adjusted free cash flow; adjusted free cash flow conversion; net debt; adjusted EBITDA (and adjusted EBITDA margin); and various measures that adjust for the impacts of special items. These non-GAAP measures are not in accordance with, nor are they a substitute for, GAAP measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in that press release. Forward-looking statements -- 2 of 24 -- 3 2023 Q4 Earnings | January 23, 2024. All rights reserved. 2024 outlook approach ▪ At this time, the 2024 guidance approach − Includes the Health Care business as part of the company for the full year and − Does not reflect the potential impact of funding the litigation payments, absent the receipt of the cash payments in the spin (each as discussed below), therefore no corresponding impact on interest expense/income ▪ The pending spin of the Health Care business remains on track for 1H 2024. 3M expects the business to be spun-off with net leverage of 3 to 3.5 times EBITDA and distribute proceeds of the financing to 3M prior to spin ▪ Management continues to support the Public Water Systems (PWS) and Combat Arms Earplug (CAE) settlements and is working with all parties and the courts to reach finalization and ultimate implementation − 3M has not selected from the options available to fund amounts due under the PWS and CAE legal settlements absent receipt of cash payments in the spin, therefore, has not forecasted the impacts of changes in net debt that may be needed to fund amounts under these settlements − For illustrative purposes only, estimated based on the current market and company expectations, in the absence of the receipt of cash payments in the Spin, the potential adjusted EPS impact from complete debt financing of the legal settlements could be up to ($0.20) − 3M will treat the dilutive EPS impact of 3M’s option to satisfy $1 billion of the CAE settlement payments via shares as an adjustment in arriving at results, adjusted for special items ▪ When considering 3M financials post spin, it is not appropriate to simply remove the Health Care business ▪ 3M will host an investor meeting following the spin of Health Care Notes on guidance -- 3 of 24 -- 4 2023 Q4 Earnings | January 23, 2024. All rights reserved. 2023 performance Executed our plan and delivered on commitments Drove operational performance and improved underlying operating margins; exceeded earnings and cash flow expectations Original Guidance January 2023 2023 Actuals Adjusted earnings per share $8.50 to $9.00 $9.24 Adjusted free cash flow conversion 90% to 100% 123% Adjusted organic sales growth Flat to -3% -3% -- 4 of 24 -- 5 2023 Q4 Earnings | January 23, 2024. All rights reserved. Reducing risk and uncertainty • Combat Arms settlement continues to achieve milestones amid strong support from claimants • PWS settlement progressing • PFAS manufacturing exit remains on track by year-end 2025; 2023 PFAS production volumes down ~20% Spinning off Health Care • Spin remains on track for first-half 2024 Advancing our priorities: Driving performance through the 3M model • Took actions to simplify the company; initiated restructuring actions that drove strong benefits in 2023 • Improved adjusted operating margins to 20.3%, which includes 140 bps headwind from pre-tax restructuring charges • Generated $6.3 billion in adjusted free cash flow, resulting in conversion of 123%, up 37 ppts year-on-year • Met or exceeded expectations throughout the year through strong operational execution • Driving future growth by streamlining our go-to-market structures and investing in attractive markets such as automotive electrification, climate technology, and industrial automation 1 2 3 -- 5 of 24 -- 6 2023 Q4 Earnings | January 23, 2024. All rights reserved. Q4 2023 performance Driving margin and cash flow through operational execution Adj. organic growth of -1.4% Includes 60 bps headwind from disposable respirator decline • End-market trends played out as anticipated – Strength in automotive OEM – Electronics stabilizing – China and consumer retail remain soft – Disposable respirator decline as expected • Adjusted operating income margin up 180 bps YoY, includes 140 bps headwind from restructuring & related charges • Continued strong operational execution • Corporate & Unallocated benefit driven by costs moved into business segments based on final full-year performance; no impact to total company operating margins • Adjusted free cash flow conversion of 145% • Remained focused on working capital improvement; inventory levels down $550M year-on-year • Continuing to invest in growth, productivity, and sustainability • Adjusted EPS up 11% YoY • Accelerated restructuring actions; Q4 EPS impact of $0.17 vs. guidance mid-point of $0.14 • Adjusted tax rate of 14.9%, or $0.06 EPS benefit vs. guidance (FY 2023 guide of ~18%; Q3 YTD actual of 18.3%; implied Q4 of ~17%) Adjusted Sales of $7.7B vs. $7.6 to $7.7B guidance Adjusted Op. Income Margin of 20.9% Adjusted EPS of $2.42 vs. $2.13 to $2.33 guidance Adjusted Free Cash Flow of $2.0B -- 6 of 24 -- 7 2023 Q4 Earnings | January 23, 2024. All rights reserved. Q4 2023 operating margin and EPS Adjusted operating margin Adjusted earnings per share Commentary Q4 2022 19.1% $2.18 Total organic growth/ productivity/other +4.0% +$0.43 Disposable respirator -0.1% -$0.03 • Decline in COVID-related disposable respirator demand Remaining organic growth/ productivity/other +4.1% +$0.46 • Benefits from productivity, sourcing actions, restructuring, spending discipline, and selling price • Partially offset by lower sales volumes and growth, productivity, and sustainability investments Restructuring & related charges -1.4% -$0.17 • Q4 2023 pre-tax charge of $109M Raw material -0.1% -$0.01 • Carryover impact of raw material, logistics, and energy cost inflation FX -0.7% -$0.07 • Net of hedge impact; Argentina devaluation Other expense/income NA +$0.02 • Primarily lower net interest Adjusted tax rate* NA +$0.05 • Q4 2023 adjusted tax rate of 14.9% versus 16.6% in Q4 2022 Shares outstanding NA -$0.01 • Average diluted shares up YoY Q4 2023 20.9% $2.42 * The effect of income taxes on items that had specific tax rates are reflected within their respective impacts in the table above. -- 7 of 24 -- 8 2023 Q4 Earnings | January 23, 2024. All rights reserved. Adjusted free cash flow $2.0B Adjusted free cash flow conversion 145% Cash returned to shareholders $0.8B Adjusted free cash flow • Q4: $2.0B, up 18% YoY • FY: $6.3B, up 30% YoY Adjusted free cash flow conversion • Q4: 145%, up 8 ppts YoY • FY: 123%, up 37 ppts YoY • FY: improvement driven by working capital, especially inventory Adjusted capital expenditures • Q4: $308M, down 32% YoY • FY: $1.4B, down 8% YoY Net debt • Q4: $10.0B, down 17% YoY Capital returned to shareholders • Q4: dividends $0.8B • FY: dividends $3.3B Q4 2023 cash flow and balance sheet -- 8 of 24 -- 2023 Q4 Earnings | January 23, 2024. All rights reserved. Business Group performance Safety & Industrial Transportation & Electronics Health Care Consumer -- 9 of 24 -- 10 2023 Q4 Earnings | January 23, 2024. All rights reserved. Business Group performance FY 2023 Organic growth Adjusted operating margin Q4 2023 Organic growth Adjusted operating margin Q4 Commentary Safety & Industrial -5.1% 22.0% -3.9% 19.7% • Double digit organic growth in roofing granules, industrial adhesives and tapes flat, all other divisions declined • Disposable respirator sales down ~$50M, and reduced segment organic growth by 1.6 ppts • Adjusted operating margin -70 bps YoY; decline driven by lower sales volume partially offset by benefits from restructuring, pricing, and strong spending discipline Transportation & Electronics* -3.5% 21.0% 2.7% 20.9% • Adjusted organic growth in advanced materials, automotive and aerospace, and commercial solutions; electronics flat and transportation safety declined • Consumer electronics stabilizing; closely monitoring demand trends • Adjusted operating margins +380 bps YoY; benefits from restructuring, pricing, and strong spending discipline Health Care 0.7% 19.6% -1.0% 18.3% • Organic growth in medical solutions; separation and purification, oral care and health information systems declined • Operating margin -190 bps YoY; decline driven by lower volumes and costs to build out the team ahead of spin • EBITDA margin of 25.5% Consumer -4.7% 18.0% -2.2% 18.0% • Organic growth in home improvement; home health and auto care, and stationery and office declined • Operating margin +100 bps YoY; benefits from restructuring, portfolio optimization, spending discipline, and productivity, partially offset by lower volume • Continued softness in consumer discretionary spend *"Transportation & Electronics” organic sales is provided on an adjusted basis while all other business segments are not provided on an adjusted basis -- 10 of 24 -- 2023 Q4 Earnings | January 23, 2024. All rights reserved. 2024 Outlook -- 11 of 24 -- 12 2023 Q4 Earnings | January 23, 2024. All rights reserved. Portfolio optimization • Complete the spin of Health Care • Execute on geographic prioritization • Prioritizing high growth, high value product portfolios • Drive growth through investments in the business Reduce risk and uncertainty • Finalize legal settlements • Progress PFAS manufacturing exit Sustainable margin and cash • Simplify and streamline the organization • Drive productivity throughout the supply chain • Relentless focus on working capital Positioning 3M for the future 2024 focus areas Drive sustainable margin and cash flow improvement through the 3M model 1 2 3 Portfolio optimization Reduce risk and uncertainty -- 12 of 24 -- 13 2023 Q4 Earnings | January 23, 2024. All rights reserved. 2024 full-year guidance Adjusted earnings per share Adjusted free cash flow conversion Adjusted organic sales growth Note: 2024 guidance approach includes the Health Care business as part of the company for the full year, but does not reflect the potential impact of funding amounts due under the Public Water System and Combat Arms Earplug settlements, absent the receipt of cash payments in the Health Care business spin. See additional details on earlier slide. $9.35 to $9.75 95% to 105% Flat to +2% (Includes ~ 1 ppt headwind from portfolio/geographic prioritization) -- 13 of 24 -- 14 2023 Q4 Earnings | January 23, 2024. All rights reserved. 2024 business group outlook Below the line items • Non-op pension expense headwind of $0.15 per share • Expected adjusted tax rate range of 18.5% to 19.5% Safety & Industrial • Organic sales growth: flat to +LSD • Industrial end-market demand mixed • Industrial Production Index (IPI) up 2% (IHS) Consumer • Organic sales growth: -LSD • Portfolio rationalization sales headwind of ~2 ppts • Consumer discretionary spending muted Transportation & Electronics • Adjusted organic sales growth: flat to +LSD • Auto builds slightly negative • Consumer electronics demand up slightly • Continued strong auto electrification growth Health Care • Organic sales growth: flat to +LSD • Procedure volume growth +LSD • Spin on track for 1H 2024 -- 14 of 24 -- 15 2023 Q4 Earnings | January 23, 2024. All rights reserved. • Macroeconomic trends similar to Q4 • Estimated combined sales headwind of ~$100M YoY from: − Consumer product portfolio rationalization, disposable respirator YoY comp and the exit of small countries • Pre-tax restructuring charge of ($75M) to ($100M), or ($0.10) to ($0.15) per share • Non-op pension headwind of $0.04 per share • Adjusted tax rate range of 20% to 21% Q1 2024 outlook Performance drivers Note: 2024 guidance approach includes the Health Care business as part of the company for the full year, but does not reflect the potential impact of funding amounts due under the Public Water System and Combat Arms Earplug settlements, absent the receipt of cash payments in the Health Care business spin. See additional details on earlier slide. Adjusted earnings per share Adjusted sales $2.00 to $2.15 ~$7.6 billion -- 15 of 24 -- 2023 Q4 Earnings | January 23, 2024. All rights reserved. Q&A Mike Roman Chairman of the Board and Chief Executive Officer Monish Patolawala President and Chief Financial Officer Bruce Jermeland Senior Vice President, Investor Relations -- 16 of 24 -- 2023 Q4 Earnings | January 23, 2024. All rights reserved. Appendix -- 17 of 24 -- 18 2023 Q4 Earnings | January 23, 2024. All rights reserved. Q4 2023 P&L GAAP ($M) Q4 2023 Q4 2022 Change Sales $8,013 $8,079 (0.8)% Gross profit $3,335 $3,494 (4.5)% % to sales 41.6% 43.2% (1.6)% SG&A $1,625 $2,146 (24.3)% % to sales 20.3% 26.5% (6.2)% R&D & related $467 $445 4.9% % to sales 5.8% 5.5% 0.3% Goodwill impairment expense $— $271 (100.0)% % to sales —% 3.4% (3.4)% Operating income (loss) $1,243 $632 96.7% % to sales 15.5% 7.8% 7.7% Net income (loss) $945 $541 74.8% Earnings (loss) per share $1.70 $0.98 74.0% Note: the term "N/M" used within the appendix references "not meaningful" for certain percent changes. -- 18 of 24 -- 19 2023 Q4 Earnings | January 23, 2024. All rights reserved. Q4 2023 adjusted sales recap Americas EMEA APAC Worldwide Organic growth 0.3 % (0.6)% (5.8)% (1.4)% Acquisitions/divestitures 0.7 % (0.6)% (0.3)% 0.2 % FX 0.5 % 5.1 % (0.9)% 0.9 % Total growth 1.5 % 3.9 % (7.0)% (0.3)% -- 19 of 24 -- 20 2023 Q4 Earnings | January 23, 2024. All rights reserved. Q4 business segment information *"Safety & Industrial", "Transportation & Electronics", "Corporate & Unallocated", "Total Operating Business Segment" and "Total" provided on an adjusted basis while “Health Care” and “Consumer” are not provided on an adjusted basis ($M) Adjusted net sales* Q4 2023 adjusted sales growth* Adjusted operating income* Adjusted operating margin* Business Groups Q4 2023 Q4 2022 Organic growth FX M&A Total sales change Q4 2023 Q4 2022 Percent change Q4 2023 Q4 2022 Safety & Industrial $2,661 $2,735 (3.9)% 1.2% —% (2.7)% $524 $556 (6.0)% 19.7% 20.4% Transportation & Electronics $1,769 $1,692 2.7% 0.5% 1.3% 4.5% $370 $291 27.6% 20.9% 17.1% Health Care $2,037 $2,044 (1.0)% 1.1% (0.4)% (0.3)% $372 $412 (9.7)% 18.3% 20.2% Consumer $1,226 $1,244 (2.2)% 0.6% —% (1.6)% $221 $212 4.2% 18.0% 17.0% Total Operating Business Segment $7,693 $7,715 $1,487 $1,471 Corporate & Unallocated $— $1 $121 $5 Total $7,693 $7,716 (1.4)% 0.9% 0.2% (0.3)% $1,608 $1,476 9.1% 20.9% 19.1% -- 20 of 24 -- 21 2023 Q4 Earnings | January 23, 2024. All rights reserved. Additional GAAP sales detail ($M) GAAP Net Sales Business Groups Q4 2023 Q4 2022 Abrasives 322 329 Automotive Aftermarket 304 309 Closure and Masking Systems 236 252 Electrical Markets 305 328 Industrial Adhesives and Tapes 531 526 Personal Safety 844 895 Roofing Granules 119 96 Total Safety & Industrial Business Group 2,661 2,735 Advanced Materials 287 296 Automotive and Aerospace 479 429 Commercial Solutions 406 390 Electronics 739 760 Transportation Safety 178 180 Total Transportation & Electronics Business Group 2,089 2,055 ($M) GAAP Net Sales Business Groups Q4 2023 Q4 2022 Health Information Systems 312 338 Medical Solutions 1,162 1,134 Oral Care 306 321 Separation and Purification Sciences 230 235 Other Health Care 27 16 Total Health Care Business Group 2,037 2,044 Construction and Home Improvement Markets 547 527 Home, Health and Auto Care 364 372 Stationery and Office 315 345 Total Consumer Business Group 1,226 1,244 Corporate and Unallocated — 1 Total 3M 8,013 8,079 -- 21 of 24 -- 22 2023 Q4 Earnings | January 23, 2024. All rights reserved. 2023 to 2025 structural reorganization actions* *Note: These are separate from 3M’s 2023 to 2025 PFAS exit actions. (($M) ) Q1 2023 Actual Q2 2023 Actual Q3 2023 Actual Q4 2023 Actual FY 2023 Actual Restructuring & related net charges $52 $212 $68 $109 $441 Net benefits (YoY) - $89 $166 $162 $417 (($M) 2024 Estimated Total Program Estimated Restructuring & related net charges $250 to $350 $700 to $900 Net benefits (YoY) $150 to $250 $700 to $900 -- 22 of 24 -- 23 2023 Q4 Earnings | January 23, 2024. All rights reserved. Quarterly 2023 adjusted operating margin progression +9.0% Q1 2023 Adjusted operating margin Q2 2023 Adjusted operating margin Q3 2023 Adjusted operating margin Q4 2023 Adjusted operating margin FY 2023 Adjusted Operating margin 2022 22.0% 21.6% 21.6% 19.1% 21.1% Total organic growth/ productivity/other -2.0% +0.9% +2.6% +4.0% +1.3% Disposable respirator/ Russia exit -1.1% -0.5% -0.4% -0.1% -0.5% Remaining organic growth/ productivity/ other -0.9% +1.4% +3.0% +4.1% +1.8% Restructuring charges -0.5% -2.7% -0.8% -1.4% -1.3% Raw materials -1.3% -0.3% -0.3% -0.1% -0.5% FX -0.3% -0.2% 0.0% -0.7% -0.3% Divestiture 0.0% 0.0% +0.1% ---- ---- Other expense/income NA NA NA NA NA Adjusted tax rate NA NA NA NA NA Shares outstanding NA NA NA NA NA 2023 17.9% 19.3% 23.2% 20.9% 20.3% Note: The above refers to a non-GAAP measure (adjusted operating margin) for periods in addition to Q4 and full year 2023. For Q1-Q3, refer to 3M’s 8-K's dated April 25, July 25, and October 24, 2023 for additional information. -- 23 of 24 -- -- 24 of 24 --